Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-Current Assets (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Non-Current Assets for 13 consecutive years, with $51.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 51.72% to $51.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $227.4 million through Dec 2025, down 54.16% year-over-year, with the annual reading at $51.6 million for FY2025, 51.72% down from the prior year.
  • Non-Current Assets hit $51.6 million in Q4 2025 for Coherus Oncology, down from $55.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $154.0 million in Q4 2023 to a low of $51.6 million in Q4 2025.
  • Historically, Non-Current Assets has averaged $93.5 million across 5 years, with a median of $85.3 million in 2023.
  • Biggest five-year swings in Non-Current Assets: surged 57.3% in 2024 and later tumbled 59.14% in 2025.
  • Year by year, Non-Current Assets stood at $77.0 million in 2021, then grew by 29.35% to $99.6 million in 2022, then soared by 54.57% to $154.0 million in 2023, then tumbled by 30.54% to $107.0 million in 2024, then plummeted by 51.72% to $51.6 million in 2025.
  • Business Quant data shows Non-Current Assets for CHRS at $51.6 million in Q4 2025, $55.6 million in Q3 2025, and $59.3 million in Q2 2025.